Neurocrine Biosciences Inc
(STU:NB3)
€
107.2
1.9 (1.8%)
Market Cap: 10.83 Bil
Enterprise Value: 10.11 Bil
PE Ratio: 35.07
PB Ratio: 4.67
GF Score: 88/100 Neurocrine Biosciences Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022 / 05:35PM GMT
Release Date Price:
€120.88
(+0.72%)
Joshua Elliott Schimmer
Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
All right. Welcome, everyone. This is Josh Schimmer from the Evercore ISI Biotech team. Please introduce our next company, Neurocrine Biosciences, Chief Executive Officer, Kevin Gorman; and Chief Financial Officer, Matt Abernethy. Gentlemen, welcome. Great to see you again. Thanks for your time.
Questions & Answers
Joshua Elliott Schimmer
Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
INGREZZA, powering through COVID, even though it feels like COVID is still impacting the psychiatry practice. Maybe give us a sense of what's worked so well as part of this recovery process or the segment of medicine that still seems very well known?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Yes, Josh, it's a good question. And good to see you, too. And thank you very much to you and to Evercore for the opportunity to speak here. Before I get going,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot